Abstract Search

ea0048p11 | Poster Presentations | SFEEU2017

Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial

McGowan Barbara , Roux Carel Le , Astrup Arne , Fujioka Ken , Greenway Frank , Lau David , Van Gaal Luc , Ortiz Rafael Violante , Wilding John , Skjoth Trine , Pi-Sunyer Xavier

Background: The 3-year part of this trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet+exercise, in delaying onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities.Methods: Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo plus 500 kcal/day deficit diet and 150...

0 shares

Endocrine Abstracts

Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial

BiosciAbstracts